Zavante recruits first patient in Zeus study of ZTI-01 to treat cUTI

US-based biopharmaceutical firm Zavante Therapeutics has randomised the first patient in the Zeus pivotal clinical study of ZTI-01 (fosfomycin for injection) to treat complicated urinary tract infections (cUTI), including acute pyelonephritis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news